What is in a name? Rethinking SMUG1 in genome maintenance
NAR Cancer · 07.10.2025 · 7 (4)
DOI: 10.1093/narcan/zcaf050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift NAR Cancer, online erschienen am 12.12.2025. Verfasst von Natalie Rudolfova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, Solna, 17165, Sweden. Hauptthemen laut MEDLINE: Uracil-DNA Glycosidase, DNA Repair, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norwegian Cancer Society, Research Council of Norway, Innovative Medicines Initiative 2 Joint Undertaking.
Abstract (Originalsprache)
Small base lesions in DNA are primarily repaired through the base excision repair pathway, which is initiated by DNA glycosylases. This review focuses on single-strand selective monofunctional uracil–DNA glycosylase (SMUG1), an enzyme whose name incompletely captures its broader biological roles. SMUG1 excises a wide range of substrates beyond uracil, shows a preference for double-stranded DNA, and has been reported to be a bifunctional DNA glycosylase with a weak lyase activity. Moreover, SMUG1 plays roles extending beyond DNA repair, including functions in RNA quality control and RNA biogenesis. Recently, genetic interactions have been described between SMUG1 and proteins that safeguard stressed replication forks, implicating a function for SMUG1 in cancer cell biology. Understanding SMUG1’s full repertoire is key to uncovering its role in genome maintenance and unlocking its potential as a therapeutic target. Here, we review the biochemical properties reported for SMUG1 and its distinct functions from other uracil–DNA glycosylases in vivo. We also highlight the emerging role of SMUG1 in cancer cells and its potential as a therapeutic target, emphasizing the need to define the genetic and molecular contexts in which its modulation may be beneficial.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Oncology and Pathology, Science for Life Laboratory, Karolinska Institute, Stockholm, Solna, 17165, Sweden.
- Center for Molecular Medicine, Karolinska Institute and Karolinska Hospital, Stockholm, 17176, Sweden.
- Department of Microbiology, Oslo University Hospital, Norway; Institute of Clinical Medicine, University of Oslo, Norway; CRESCO-Centre for Embryology and Healthy Development, University of Oslo, 0424 Oslo, Norway.
- Department of Biotechnology and Nanomedicine, SINTEF Industry,7034 Trondheim, Norway.
ORCID-Profile: Nicola P Montaldo, Torkild Visnes, Hilde Loge Nilsen
Förderung
- Norwegian Cancer Society
- Research Council of Norway
- Innovative Medicines Initiative 2 Joint Undertaking
- European Union
- EFPIA
- Ontario Institute for Cancer Research
- Royal Institution for the Advancement of Learning McGill University
- Kungliga Tekniska Högskolan
Zitieren
APA
Rudolfova, N., Skjetne, A. M., Montaldo, N. P., Visnes, T., Nilsen, H. L., & Michel, M. (2025). What is in a name? Rethinking SMUG1 in genome maintenance. NAR Cancer, 7(4). https://doi.org/10.1093/narcan/zcaf050
Vancouver
Rudolfova N, Skjetne AM, Montaldo NP, Visnes T, Nilsen HL, Michel M. What is in a name? Rethinking SMUG1 in genome maintenance. NAR Cancer. 2025;7(4). doi:10.1093/narcan/zcaf050
BibTeX
@article{Rudolfova2025,
author = {Rudolfova, Natalie and Skjetne, Alexander Myhr and Montaldo, Nicola P and Visnes, Torkild and Nilsen, Hilde Loge and Michel, Maurice},
title = {What is in a name? Rethinking SMUG1 in genome maintenance},
journal = {NAR Cancer},
year = {2025},
volume = {7},
number = {4},
doi = {10.1093/narcan/zcaf050}
}
EUVIMED